|
|
Cangene Corporation - Comparative Business Analysis Snapshot
Business Description
Cangene Corporation. The Group's principal activities are to develop and distribute hyperimmune products and recombinant biopharmaceuticals. Hyperimmune products are specialty antibody preparations made from plasma products. Recombinant protein products are therapeutic proteins made by introducing a particular gene into a host organism, which in turn produces the protein of interest. The Group operates in two segments namely Contract R&D and Manufacturing and Biopharmaceutical Operations. Biopharmaceutical Operations include in-house licensed product sales and royalties and related party research and development. Contract R&D and Manufacturing provides products and services to third party clients. The Group develops and supplies antibody products that may aid in the fight against challenging infectious diseases such as smallpox, Ebola, anthrax, West Nile and hepatitis. The Group markets its products in Canada, the United States and other foreign countries.
Competitor Analysis
This analysis compares Cangene Corporation with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
|
|
|
|
